Prognostic Metabolic Signatures in Pancreatic Ductal Adenocarcinoma (PDAC).

被引：0
|
作者：
Karasinska, Joanna [1 ]
Kalloger, Steve [2 ]
Wong, Hui-Li [3 ]
Renouf, Daniel [3 ]
Schaeffer, David [4 ]
机构：
[1] Pancreas Ctr BC, Vancouver, BC, Canada
[2] Univ British Columbia, Vancouver, BC, Canada
[3] British Columbia Canc Agcy, Vancouver, BC, Canada
[4] Vancouver Gen Hosp, Vancouver, BC, Canada
来源：
LABORATORY INVESTIGATION | 2018年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1893
引用
收藏
页码：680 / 680
页数：1
相关论文
共 50 条
  • [21] Plasma KRAS as a biomarker for pancreatic ductal adenocarcinoma (PDAC).
    Krantz, Benjamin A.
    Tsui, Dana
    Lowery, Maeve Aine
    Capanu, Marinela
    Yu, Kenneth H.
    Kelsen, David Paul
    Gedvilaite, Erika
    Zhang, Liguo
    Selcuklu, S. Duygu
    You, Daoqi
    Pernicka, Jennifer S. Golia
    Do, Richard K. G.
    Iacobuzio-Donahue, Christine A.
    O'Reilly, Eileen Mary
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [22] pH Regulatory Transporters in Pancreatic Ductal Adenocarcinoma (PDAC)
    Kong, Su Chii
    Christensen, Sandra
    Hoffmann, Else Kay
    Novak, Ivana
    Pedersen, Stine Falsig
    [J]. FASEB JOURNAL, 2013, 27
  • [23] Diagnostic and Prognostic Performance of Metabolic Signatures in Pancreatic Ductal Adenocarcinoma: The Clinical Application of Quantitative NextGen Mass Spectrometry
    D'Amora, Paulo
    Silva, Ismael D. C. G.
    Evans, Steven S.
    Nagourney, Adam J.
    Kirby, Katharine A.
    Herrmann, Brett
    Cavalheiro, Daniela
    Francisco, Federico R.
    Bernard, Paula J.
    Nagourney, Robert A.
    [J]. METABOLITES, 2024, 14 (03)
  • [24] Characterization of primary and metastatic pancreatic tumors in pancreatic ductal adenocarcinoma (PDAC)
    Martinez-Muniz, Andres E.
    Sivanand, Sharanya
    Vander Heiden, Matthew
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [25] Serum p53 antibodies as a prognostic marker in patients with pancreatic ductal adenocarcinoma (PDAC)
    Zhang, Xibo
    Shang, Haitao
    Li, Zhonglian
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (08): : 8376 - 8381
  • [26] Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma
    Tang, Rong
    Liu, Xiaomeng
    Liang, Chen
    Hua, Jie
    Xu, Jin
    Wang, Wei
    Meng, Qingcai
    Liu, Jiang
    Zhang, Bo
    Yu, Xianjun
    Shi, Si
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [27] Oral cavity immune response in pancreatic ductal adenocarcinoma (PDAC)
    Marquez, J. P.
    Lucero-Diaz, P. A.
    Matute-Briseno, J. A.
    Rosas-Delgado, M. O.
    Camacho-Hernandez, A.
    Cortez-Vargas, Y.
    Nava-Sanchez, I.
    Montano, G. T.
    Montijo-Fernandez, L. N.
    Perez-Astorga, M. A.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 44 - 44
  • [28] Comprehensive genomic analysis in metastatic pancreatic ductal adenocarcinoma (PDAC).
    Wong, Hui-Li
    Jones, Martin
    Eirew, Peter
    Karasinska, Joanna
    Schrader, Kasmintan A.
    Lim, Howard John
    Shen, Yaoqing
    Jones, Steven
    Yip, Stephen
    Laskin, Janessa J.
    Marra, Marco
    Schaeffer, David F.
    Renouf, Daniel John
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [29] Neuroplastic Changes in a Mouse Model of Pancreatic Ductal Adenocarcinoma (PDAC)
    Stopczynski, Rachelle E.
    DePinho, Ronald A.
    Ying, Haoqiang
    Schwartz, Erica S.
    Albers, Kathryn M.
    Davis, Brian M.
    Bielefeldt, Klaus
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S62 - S62
  • [30] Hereditary pancreatitis (HP) and the risk of pancreatic ductal adenocarcinoma (PDAC)
    Howes, N
    Lerch, MM
    Charnley, R
    Mössner, J
    Endres, S
    Deviere, J
    Verreman, V
    Lucidi, V
    Ohla, A
    Ihse, I
    Imrie, C
    Steenbergan, W
    Poll, A
    Greenhalf, W
    Ellis, I
    Mountford, R
    Whitcomb, DC
    Neoptolemos, JP
    [J]. GUT, 2002, 50 : A43 - A43
12345